Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Regeneron Pharmaceuticals Inc. REGN

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:REGN)

Fundamentals Snapshot (NDAQ:REGN)

Current News (NDAQ:REGN)

Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis

GlobeNewswire 22 hours ago

Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition

GlobeNewswire 3 days ago

Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023

GlobeNewswire January 3, 2023

Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer

PR Newswire December 23, 2022

Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine

PR Newswire December 21, 2022

Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

PR Newswire December 19, 2022

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis

PR Newswire December 16, 2022

Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis

PR Newswire December 15, 2022

Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial

PR Newswire December 12, 2022

Bullboard Posts (NDAQ:REGN)

Bonvoyage12.....Lying Pumper

Ignore this clown as he posts lies trying to mislead investors about the actual state of the company...he also posts this same BS on...
Mil_Man54 - December 26, 2020

Vaccine Stocks - Can the President Overrule the FDA?

An approval cycle that typically takes years is being expedited. In the case of the 2020 pandemic, the FDA  has shortened standard...
schoolofrock - October 7, 2020

SmallCapPaul - October 6, 2020

Next multibagger
goregil - February 14, 2019

Seeking another regn

Seeking a penny stock that could soar into a stock worth hundreds of dollars Theralase may be that stock v.tlt  they appear to have...
goregil - February 10, 2019

Regeneron & Sanofi Announce Praluent To Get Priority Review

[url= ]http...
RickLejeune - January 26, 2015